PFIZER $PFE (+1,49 %) GUIDES FY25 BASICALLY IN-LINE, FOCUSES ON COST SAVINGS

- FY25 Revenue: $61B-$64B (vs $62.9B expected)

- Adj EPS: $2.80-$3.00 (vs $2.90 expected)

- Pfizer sees $500M additional savings in 2025, building on its $4B cost realignment.

- Manufacturing optimization on track for cost improvements in H2'25.

-IRA-related changes to Part D expected to impact revenue by ~$1B YoY.